schliessen

Filtern

 

Bibliotheken

The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study

Aims/hypothesis Some studies have reported that annual change in eGFR (eGFR slope) is associated with the future risk of end-stage kidney disease, cardiovascular disease and death in general or chronic kidney disease cohorts. However, the benefits of using eGFR slopes for prediction of major clinica... Full description

Journal Title: Diabetologia 2019-07-13, Vol.62 (11), p.1988-1997
Main Author: Oshima, Megumi
Other Authors: Jun, Min , Ohkuma, Toshiaki , Toyama, Tadashi , Wada, Takashi , Cooper, Mark E , Hadjadj, Samy , Hamet, Pavel , Harrap, Stephen , Mancia, Giuseppe , Marre, Michel , Williams, Bryan , Chalmers, John , Woodward, Mark , Perkovic, Vlado
Format: Electronic Article Electronic Article
Language: English
Subjects:
End
Publisher: Berlin/Heidelberg: Springer Berlin Heidelberg
ID: ISSN: 0012-186X
Link: https://www.ncbi.nlm.nih.gov/pubmed/31302707
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_2258159431
title: The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study
format: Article
creator:
  • Oshima, Megumi
  • Jun, Min
  • Ohkuma, Toshiaki
  • Toyama, Tadashi
  • Wada, Takashi
  • Cooper, Mark E
  • Hadjadj, Samy
  • Hamet, Pavel
  • Harrap, Stephen
  • Mancia, Giuseppe
  • Marre, Michel
  • Williams, Bryan
  • Chalmers, John
  • Woodward, Mark
  • Perkovic, Vlado
subjects:
  • Article
  • Cardiovascular disease
  • eGFR slope
  • End
  • End-stage kidney disease
  • Health aspects
  • Human Physiology
  • Internal Medicine
  • Medicine
  • Medicine & Public Health
  • Metabolic Diseases
  • Mortality
  • stage kidney disease
  • Surrogate endpoint
  • Type 2 diabetes
ispartof: Diabetologia, 2019-07-13, Vol.62 (11), p.1988-1997
description: Aims/hypothesis Some studies have reported that annual change in eGFR (eGFR slope) is associated with the future risk of end-stage kidney disease, cardiovascular disease and death in general or chronic kidney disease cohorts. However, the benefits of using eGFR slopes for prediction of major clinical outcomes in diabetes are unclear. Methods We used data from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial and the ADVANCE Post-Trial Observational Study (ADVANCE-ON). After excluding the first 4 months during which an acute fall in eGFR was induced by the initiation of an ACE inhibitor and diuretic combination agent, eGFR slopes were estimated by linear mixed models, using three measurements of eGFR at 4, 12 and 24 months after randomisation over 20 months, and categorised according to quartiles. Cox regression models were used to evaluate adjusted HRs for the study’s primary outcome, a composite of major renal events, major macrovascular events and all-cause mortality during the subsequent follow-up from 24 months after randomisation. Results A total of 8,879 participants (80%) were included in this cohort. The mean age was 65.6 years (SD 6.3), the mean eGFR was 75 ml min −1 (1.73 m) −2 (SD 17) and the median urinary albumin/creatinine ratio was 14 μg/mg (interquartile range 7–38). The mean eGFR slope was −0.63 ml min −1 (1.73 m) −2  year −1 (SD 1.75). Over a median follow-up of 7.6 years following the 20-month eGFR slope ascertainment period, 2,221 participants (25%) met the primary outcome. An annual substantial decrease in eGFR (lowest 25%, 0.33) had no significant association with the risk of the primary outcome (HR 0.96 [95% CI 0.86, 1.07]). Conclusions/interpretation Our study supports the utility of eGFR slope in type 2 diabetes as a surrogate endpoint for renal outcomes, as well as a prognostic factor for identifying individuals at high risk of cardiovascular disease and all-cause mortality. Trial registry number ClinicalTrials.gov registration no. NCT00145925 and no. NCT00949286
language: eng
source:
identifier: ISSN: 0012-186X
fulltext: no_fulltext
issn:
  • 0012-186X
  • 1432-0428
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.6362164
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_2258159431
sourceformatXML
sourcesystemPC
galeidA603510686
sourcerecordidA603510686
originalsourceidFETCH-LOGICAL-1615t-2015c48128491d856e54a827363615eb5f589dd2103dd638b88bc9b28094b4600
addsrcrecordideNp9klFrFDEUhQdRbK3-AF8kj4JMTTKZbMYHYaltFUoLUsW3kEnutKmzyZpkWvZH-J-9u1tbKyjzMDD3nC9nbk5VvWR0n1E6e5spZbytKetq0QlVi0fVLhMNr6ng6nG1ux7XTMlvO9WznK8opU0r5NNqp2EN5TM6261-nl8CSTCa4mPIl35Jeig3AIHA8dFnkse4BGKCI3nqM_yYIBSSfP5O4kCuTbbTaBKJU7FxAXkjNONYWzNlIIuYihl9WREfSFkhiBPnDR4A-R0pePD8w9f56cFhfXZKcpnc6nn1ZDBjhhe3773qy9Hh-cHH-uTs-NPB_KRmkrWl5pS1VijGleiYU62EVhjFZ41scA59O7Sqc44z2jgnG9Ur1duu54p2oheS0r3q_Za7nPoFOIt_lcyol8kvTFrpaLx-OAn-Ul_Eay0VbRVvEXC6BeB6gvEJHnhdgKIduGmpbwaNt6A7AUapGWMdE9J2gxEMk9leDp1wrpsh8PVtohRxy7nohc8WxtEEiFPWnLeKtZ1oGEr3t9ILM4L2YYgY0eLjYOFtDDB4_D6XeNmMSiXRwLYGm2LOCYa7sIzqdZH0tkgai6TXRdICPa_-3NCd43dz7qEZR-EC0j0USXyNmqfiLUbZIJduQM-bf3g2-rVRcs3YxoFq_pf6Kk4pYC_-k_sXe1TxYA
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid2258159431
display
typearticle
titleThe relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study
creatorOshima, Megumi ; Jun, Min ; Ohkuma, Toshiaki ; Toyama, Tadashi ; Wada, Takashi ; Cooper, Mark E ; Hadjadj, Samy ; Hamet, Pavel ; Harrap, Stephen ; Mancia, Giuseppe ; Marre, Michel ; Williams, Bryan ; Chalmers, John ; Woodward, Mark ; Perkovic, Vlado
creatorcontribOshima, Megumi ; Jun, Min ; Ohkuma, Toshiaki ; Toyama, Tadashi ; Wada, Takashi ; Cooper, Mark E ; Hadjadj, Samy ; Hamet, Pavel ; Harrap, Stephen ; Mancia, Giuseppe ; Marre, Michel ; Williams, Bryan ; Chalmers, John ; Woodward, Mark ; Perkovic, Vlado ; ADVANCE Collaborative Group ; on behalf of the ADVANCE Collaborative Group
descriptionAims/hypothesis Some studies have reported that annual change in eGFR (eGFR slope) is associated with the future risk of end-stage kidney disease, cardiovascular disease and death in general or chronic kidney disease cohorts. However, the benefits of using eGFR slopes for prediction of major clinical outcomes in diabetes are unclear. Methods We used data from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial and the ADVANCE Post-Trial Observational Study (ADVANCE-ON). After excluding the first 4 months during which an acute fall in eGFR was induced by the initiation of an ACE inhibitor and diuretic combination agent, eGFR slopes were estimated by linear mixed models, using three measurements of eGFR at 4, 12 and 24 months after randomisation over 20 months, and categorised according to quartiles. Cox regression models were used to evaluate adjusted HRs for the study’s primary outcome, a composite of major renal events, major macrovascular events and all-cause mortality during the subsequent follow-up from 24 months after randomisation. Results A total of 8,879 participants (80%) were included in this cohort. The mean age was 65.6 years (SD 6.3), the mean eGFR was 75 ml min −1 (1.73 m) −2 (SD 17) and the median urinary albumin/creatinine ratio was 14 μg/mg (interquartile range 7–38). The mean eGFR slope was −0.63 ml min −1 (1.73 m) −2  year −1 (SD 1.75). Over a median follow-up of 7.6 years following the 20-month eGFR slope ascertainment period, 2,221 participants (25%) met the primary outcome. An annual substantial decrease in eGFR (lowest 25%, <−1.63 ml min −1 [1.73 m] −2  year −1 ) was significantly associated with the subsequent risk of the primary outcome (HR 1.30 [95% CI 1.17, 1.43]) compared with a stable change in eGFR (middle 50%, −1.63 to 0.33). An annual substantial increase in eGFR (highest 25%, >0.33) had no significant association with the risk of the primary outcome (HR 0.96 [95% CI 0.86, 1.07]). Conclusions/interpretation Our study supports the utility of eGFR slope in type 2 diabetes as a surrogate endpoint for renal outcomes, as well as a prognostic factor for identifying individuals at high risk of cardiovascular disease and all-cause mortality. Trial registry number ClinicalTrials.gov registration no. NCT00145925 and no. NCT00949286
identifier
0ISSN: 0012-186X
1EISSN: 1432-0428
2DOI: 10.1007/s00125-019-4948-4
3PMID: 31302707
languageeng
publisherBerlin/Heidelberg: Springer Berlin Heidelberg
subjectArticle ; Cardiovascular disease ; eGFR slope ; End ; End-stage kidney disease ; Health aspects ; Human Physiology ; Internal Medicine ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Mortality ; stage kidney disease ; Surrogate endpoint ; Type 2 diabetes
ispartofDiabetologia, 2019-07-13, Vol.62 (11), p.1988-1997
rights
0The Author(s) 2019
1COPYRIGHT 2019 Springer
lds50peer_reviewed
oafree_for_read
citesFETCH-LOGICAL-1615t-2015c48128491d856e54a827363615eb5f589dd2103dd638b88bc9b28094b4600
orcidid0000-0002-4108-5229
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31302707$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Oshima, Megumi
1Jun, Min
2Ohkuma, Toshiaki
3Toyama, Tadashi
4Wada, Takashi
5Cooper, Mark E
6Hadjadj, Samy
7Hamet, Pavel
8Harrap, Stephen
9Mancia, Giuseppe
10Marre, Michel
11Williams, Bryan
12Chalmers, John
13Woodward, Mark
14Perkovic, Vlado
15ADVANCE Collaborative Group
16on behalf of the ADVANCE Collaborative Group
title
0The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study
1Diabetologia
addtitle
0Diabetologia
1Diabetologia
descriptionAims/hypothesis Some studies have reported that annual change in eGFR (eGFR slope) is associated with the future risk of end-stage kidney disease, cardiovascular disease and death in general or chronic kidney disease cohorts. However, the benefits of using eGFR slopes for prediction of major clinical outcomes in diabetes are unclear. Methods We used data from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial and the ADVANCE Post-Trial Observational Study (ADVANCE-ON). After excluding the first 4 months during which an acute fall in eGFR was induced by the initiation of an ACE inhibitor and diuretic combination agent, eGFR slopes were estimated by linear mixed models, using three measurements of eGFR at 4, 12 and 24 months after randomisation over 20 months, and categorised according to quartiles. Cox regression models were used to evaluate adjusted HRs for the study’s primary outcome, a composite of major renal events, major macrovascular events and all-cause mortality during the subsequent follow-up from 24 months after randomisation. Results A total of 8,879 participants (80%) were included in this cohort. The mean age was 65.6 years (SD 6.3), the mean eGFR was 75 ml min −1 (1.73 m) −2 (SD 17) and the median urinary albumin/creatinine ratio was 14 μg/mg (interquartile range 7–38). The mean eGFR slope was −0.63 ml min −1 (1.73 m) −2  year −1 (SD 1.75). Over a median follow-up of 7.6 years following the 20-month eGFR slope ascertainment period, 2,221 participants (25%) met the primary outcome. An annual substantial decrease in eGFR (lowest 25%, <−1.63 ml min −1 [1.73 m] −2  year −1 ) was significantly associated with the subsequent risk of the primary outcome (HR 1.30 [95% CI 1.17, 1.43]) compared with a stable change in eGFR (middle 50%, −1.63 to 0.33). An annual substantial increase in eGFR (highest 25%, >0.33) had no significant association with the risk of the primary outcome (HR 0.96 [95% CI 0.86, 1.07]). Conclusions/interpretation Our study supports the utility of eGFR slope in type 2 diabetes as a surrogate endpoint for renal outcomes, as well as a prognostic factor for identifying individuals at high risk of cardiovascular disease and all-cause mortality. Trial registry number ClinicalTrials.gov registration no. NCT00145925 and no. NCT00949286
subject
0Article
1Cardiovascular disease
2eGFR slope
3End
4End-stage kidney disease
5Health aspects
6Human Physiology
7Internal Medicine
8Medicine
9Medicine & Public Health
10Metabolic Diseases
11Mortality
12stage kidney disease
13Surrogate endpoint
14Type 2 diabetes
issn
00012-186X
11432-0428
fulltextfalse
rsrctypearticle
creationdate2019
recordtypearticle
recordideNp9klFrFDEUhQdRbK3-AF8kj4JMTTKZbMYHYaltFUoLUsW3kEnutKmzyZpkWvZH-J-9u1tbKyjzMDD3nC9nbk5VvWR0n1E6e5spZbytKetq0QlVi0fVLhMNr6ng6nG1ux7XTMlvO9WznK8opU0r5NNqp2EN5TM6261-nl8CSTCa4mPIl35Jeig3AIHA8dFnkse4BGKCI3nqM_yYIBSSfP5O4kCuTbbTaBKJU7FxAXkjNONYWzNlIIuYihl9WREfSFkhiBPnDR4A-R0pePD8w9f56cFhfXZKcpnc6nn1ZDBjhhe3773qy9Hh-cHH-uTs-NPB_KRmkrWl5pS1VijGleiYU62EVhjFZ41scA59O7Sqc44z2jgnG9Ur1duu54p2oheS0r3q_Za7nPoFOIt_lcyol8kvTFrpaLx-OAn-Ul_Eay0VbRVvEXC6BeB6gvEJHnhdgKIduGmpbwaNt6A7AUapGWMdE9J2gxEMk9leDp1wrpsh8PVtohRxy7nohc8WxtEEiFPWnLeKtZ1oGEr3t9ILM4L2YYgY0eLjYOFtDDB4_D6XeNmMSiXRwLYGm2LOCYa7sIzqdZH0tkgai6TXRdICPa_-3NCd43dz7qEZR-EC0j0USXyNmqfiLUbZIJduQM-bf3g2-rVRcs3YxoFq_pf6Kk4pYC_-k_sXe1TxYA
startdate20190713
enddate20190713
creator
0Oshima, Megumi
1Jun, Min
2Ohkuma, Toshiaki
3Toyama, Tadashi
4Wada, Takashi
5Cooper, Mark E
6Hadjadj, Samy
7Hamet, Pavel
8Harrap, Stephen
9Mancia, Giuseppe
10Marre, Michel
11Williams, Bryan
12Chalmers, John
13Woodward, Mark
14Perkovic, Vlado
general
0Springer Berlin Heidelberg
1Springer
scope
0C24
1NPM
2AAYXX
3CITATION
4BSHEE
57X8
6BOBZL
7CLFQK
85PM
orcididhttps://orcid.org/0000-0002-4108-5229
sort
creationdate20190713
titleThe relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study
authorOshima, Megumi ; Jun, Min ; Ohkuma, Toshiaki ; Toyama, Tadashi ; Wada, Takashi ; Cooper, Mark E ; Hadjadj, Samy ; Hamet, Pavel ; Harrap, Stephen ; Mancia, Giuseppe ; Marre, Michel ; Williams, Bryan ; Chalmers, John ; Woodward, Mark ; Perkovic, Vlado
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1615t-2015c48128491d856e54a827363615eb5f589dd2103dd638b88bc9b28094b4600
rsrctypearticles
prefilterarticles
languageeng
creationdate2019
topic
0Article
1Cardiovascular disease
2eGFR slope
3End
4End-stage kidney disease
5Health aspects
6Human Physiology
7Internal Medicine
8Medicine
9Medicine & Public Health
10Metabolic Diseases
11Mortality
12stage kidney disease
13Surrogate endpoint
14Type 2 diabetes
toplevelpeer_reviewed
creatorcontrib
0Oshima, Megumi
1Jun, Min
2Ohkuma, Toshiaki
3Toyama, Tadashi
4Wada, Takashi
5Cooper, Mark E
6Hadjadj, Samy
7Hamet, Pavel
8Harrap, Stephen
9Mancia, Giuseppe
10Marre, Michel
11Williams, Bryan
12Chalmers, John
13Woodward, Mark
14Perkovic, Vlado
15ADVANCE Collaborative Group
16on behalf of the ADVANCE Collaborative Group
collection
0Springer Journals Complete - Open Access
1PubMed
2CrossRef
3Academic OneFile (A&I only)
4MEDLINE - Academic
5OpenAIRE (Open Access)
6OpenAIRE
7PubMed Central (Full Participant titles)
jtitleDiabetologia
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Oshima, Megumi
1Jun, Min
2Ohkuma, Toshiaki
3Toyama, Tadashi
4Wada, Takashi
5Cooper, Mark E
6Hadjadj, Samy
7Hamet, Pavel
8Harrap, Stephen
9Mancia, Giuseppe
10Marre, Michel
11Williams, Bryan
12Chalmers, John
13Woodward, Mark
14Perkovic, Vlado
aucorp
0ADVANCE Collaborative Group
1on behalf of the ADVANCE Collaborative Group
formatjournal
genrearticle
ristypeJOUR
atitleThe relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study
jtitleDiabetologia
stitleDiabetologia
addtitleDiabetologia
date2019-07-13
risdate2019
volume62
issue11
spage1988
epage1997
pages1988-1997
issn0012-186X
eissn1432-0428
abstractAims/hypothesis Some studies have reported that annual change in eGFR (eGFR slope) is associated with the future risk of end-stage kidney disease, cardiovascular disease and death in general or chronic kidney disease cohorts. However, the benefits of using eGFR slopes for prediction of major clinical outcomes in diabetes are unclear. Methods We used data from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial and the ADVANCE Post-Trial Observational Study (ADVANCE-ON). After excluding the first 4 months during which an acute fall in eGFR was induced by the initiation of an ACE inhibitor and diuretic combination agent, eGFR slopes were estimated by linear mixed models, using three measurements of eGFR at 4, 12 and 24 months after randomisation over 20 months, and categorised according to quartiles. Cox regression models were used to evaluate adjusted HRs for the study’s primary outcome, a composite of major renal events, major macrovascular events and all-cause mortality during the subsequent follow-up from 24 months after randomisation. Results A total of 8,879 participants (80%) were included in this cohort. The mean age was 65.6 years (SD 6.3), the mean eGFR was 75 ml min −1 (1.73 m) −2 (SD 17) and the median urinary albumin/creatinine ratio was 14 μg/mg (interquartile range 7–38). The mean eGFR slope was −0.63 ml min −1 (1.73 m) −2  year −1 (SD 1.75). Over a median follow-up of 7.6 years following the 20-month eGFR slope ascertainment period, 2,221 participants (25%) met the primary outcome. An annual substantial decrease in eGFR (lowest 25%, <−1.63 ml min −1 [1.73 m] −2  year −1 ) was significantly associated with the subsequent risk of the primary outcome (HR 1.30 [95% CI 1.17, 1.43]) compared with a stable change in eGFR (middle 50%, −1.63 to 0.33). An annual substantial increase in eGFR (highest 25%, >0.33) had no significant association with the risk of the primary outcome (HR 0.96 [95% CI 0.86, 1.07]). Conclusions/interpretation Our study supports the utility of eGFR slope in type 2 diabetes as a surrogate endpoint for renal outcomes, as well as a prognostic factor for identifying individuals at high risk of cardiovascular disease and all-cause mortality. Trial registry number ClinicalTrials.gov registration no. NCT00145925 and no. NCT00949286
copBerlin/Heidelberg
pubSpringer Berlin Heidelberg
pmid31302707
doi10.1007/s00125-019-4948-4
orcididhttps://orcid.org/0000-0002-4108-5229
oafree_for_read